Tag: semaglutide
-
Drugmakers Say GLP-1 Weight-Loss Drugs Show Signs of Slowing Biological Aging
Eli Lilly and Novo Nordisk report a roughly two- to three-year reduction in biological age, while researchers continue to probe side effects including hair loss, nail disorders and a disputed vision-loss link.
Science & TechnologyHealthBusinessPolitics and GovernmentArtificial IntelligenceMedical ScienceEnergyComputers and InternetMilitaryLegalUSASocial IssuesPharmaceuticalsEnvironmentClimate ChangeEconomy MIT Technology ReviewAI refusalGLP-1 weight-loss drugsEnvision EnergyAnthropic ClaudeOpenAI revenue forecastMITsciencetechnologyGLP-1 drugsbiological ageEli LillyNovo Nordiskweight lossWorld Health Organizationchildhood obesityOpenAIMistralGoogle data center Finlandbiological agingaging clockssemaglutide
-
NIH Researchers Identify Pathway to Enhance GLP-1 Weight Loss Effects
NIH scientists have identified key intracellular signaling pathways in neurons that influence GLP-1 drug semaglutide's weight-loss effects. Modulating these pathways, particularly cAMP levels, could lead to more sustained and effective treatments for obesity.
HealthScience & TechnologyPolitics and GovernmentMedical ScienceFederal Government NIHGLP-1SemaglutideWeight LosscAMPNIDDKRoflumilastNational Institutes of Health